Association of a polymorphism in the ABCB1 gene with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue 6, 2009, Pages 422-424

  Westerlund, Marie ^a   Belin, Andrea Carmine ^a   Anvret, Anna ^a   Håkansson, Anna ^b   Nissbrandt, Hans ^b   Lind, Charlotta ^c   Sydow, Olof ^c   Olson, Lars ^a   Galter, Dagmar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood brain barrier; Multi drug resistance 1; P gp; Polymorphism; Pyrosequencing

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; EXON; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 67449091266     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.11.010     Document Type: Article

References (30)

1. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86 (1989) 695-698
2. Kartner N., Riordan J.R., and Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221 (1983) 1285-1288
3. Ceckova-Novotna M., Pavek P., and Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 22 (2006) 400-410
4. Ernest S., Rajaraman S., Megyesi J., and Bello-Reuss E.N. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 77 (1997) 284-289
5. Sugawara I., Akiyama S., Scheper R.J., and Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 112 (1997) 23-31
6. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84 (1987) 7735-7738
7. Thörn M., Finnström N., Lundgren S., Rane A., and Lööf L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60 (2005) 54-60
8. Westerlund M., Belin A.C., Olson L., and Galter D. Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell Tissue Res 334 (2008) 179-185
9. Wioland M.A., Fleury-Feith J., Corlieu P., Commo F., Monceaux G., Lacau-St-Guily J., et al. CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J Histochem Cytochem 48 (2000) 1215-1222
10. Callen D.F., Baker E., Simmers R.N., Seshadri R., and Roninson I.B. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 77 (1987) 142-144
11. Hoffmeyer S., Burk O., von R.O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97 (2000) 3473-3478
12. Gerloff T., Schaefer M., Johne A., Oselin K., Meisel C., Cascorbi I., et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 54 (2002) 610-616
13. Nakamura T., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Shirakawa T., et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71 (2002) 297-303
14. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72 (2002) 572-583
15. Daniel S.E., and Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39 (1993) 165-172
16. Ronaghi M., Uhlen M., and Nyren P. A sequencing method based on real-time pyrophosphate. Science 281 363 (1998) 365
17. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25 (2003) 115-121
18. Lee C.G., Tang K., Cheung Y.B., Wong L.P., Tan C., Shen H., et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J Med Genet 41 (2004) e60
19. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 (2007) 525-528
20. Nackley A.G., Shabalina S.A., Tchivileva I.E., Satterfield K., Korchynskyi O., Makarov S.S., et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314 (2006) 1930-1933
21. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12 (2002) 529-534
22. Tan E.K., Drozdzik M., Bialecka M., Honczarenko K., Klodowska-Duda G., Teo Y.Y., et al. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci Lett 372 (2004) 240-244
23. Tan E.K., Chan D.K., Ng P.W., Woo J., Teo Y.Y., Tang K., et al. Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 62 (2005) 460-464
24. Drozdzik M., Bialecka M., Mysliwiec K., Honczarenko K., Stankiewicz J., and Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13 (2003) 259-263
25. Toda T., Momose Y., Murata M., Tamiya G., Yamamoto M., Hattori N., et al. Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol (2003) 250 Suppl. 3: III40-III43
26. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 51 (2002) 133-136
27. Zimprich F., Sunder-Plassmann R., Stogmann E., Gleiss A., Dal-Bianco A., Zimprich A., et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63 (2004) 1087-1089
28. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57 (2005) 176-179
29. Uhr M., Ebinger M., Rosenhagen M.C., and Grauer M.T. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci Lett 383 (2005) 73-76
30. Martel F., Martins M.J., Hipolito-Reis C., and Azevedo I. Inward transport of [3H]-1-methyl-4-phenylpyridinium in rat isolated hepatocytes: putative involvement of a P-glycoprotein transporter. Br J Pharmacol 119 (1996) 1519-1524